卓越新能(688196.SH):擬在泰國投資建設生物能源生產線項目
格隆匯7月8日丨卓越新能(688196.SH)公佈,公司擬投資人民幣7億元,用於在泰國春武里府建設生物能源生產線項目,建設內容包括年產30萬噸生物柴油生產裝置、年產10萬噸HVO(烴基生物柴油)/SAF(生物航空燃料)聯合生產裝置及相應配套裝置。本項目將分期實施建設,一期先行完成年產30萬噸生物柴油生產線及配套裝置的建設,由卓越新能源(泰國)有限責任公司(簡稱“泰國卓越”)負責項目具體落地實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.